2022
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients
Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.Peer-Reviewed Original ResearchConceptsRECIST response rateProgression-free survivalMetastatic/recurrent diseaseOverall survivalInduction chemotherapyRecurrent diseaseNeck cancerMetastatic/recurrent headPFS/overall survivalMean progression-free survivalSuccessful induction rateMean overall survivalPercent of patientsCases of metastasisFrail subsetWeekly paclitaxelFrail patientsAdult patientsElderly patientsPerformance statusRecurrent headInduction cohortInduction groupPatientsRecurrent group
2021
Renal sarcomas: Epidemiology, treatment and outcomes.
Uhlig J, Uhlig A, Deshpande H, Hurwitz M, Humphrey P, Kim K. Renal sarcomas: Epidemiology, treatment and outcomes. Journal Of Clinical Oncology 2021, 39: 362-362. DOI: 10.1200/jco.2021.39.6_suppl.362.Peer-Reviewed Original ResearchPrimitive neuroectodermal tumorRenal sarcomaOverall survivalMalignant rhabdoid tumorSEER databaseSurgical resectionSystemic therapyDistant metastasisTumor diameterSarcoma subtypesIncidence rateRenal malignancyAge-adjusted incidence ratesCox proportional hazards modelMedian tumor diameterAdvanced T stageDifferent histological subtypesProportional hazards modelSolitary fibrous tumorWorse OSAdult patientsFemale predominanceMale predominanceMedian ageOS rates